您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Alosetron
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Alosetron
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Alosetron图片
CAS NO:122852-42-0
包装与价格：
包装价格(元)
10mg电议
50mg电议

产品介绍
Alosetron (GR 68755) 是一种有效且高度选择性的血清素 5-HT3 受体拮抗剂。
Cas No.122852-42-0
别名阿洛司琼; GR 68755; GR 68755X
化学名5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one
Canonical SMILESCC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
分子式C17H18N4O
分子量294.35
溶解度Soluble in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Alosetron (GR 68755) is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.IC50 Value: Target: 5-HT ReceptorAlosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia.

References:
[1]. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome By Harris, Lucinda A.; Chang, Lin From Women's Health (2007), 3(1), 15-27.
[2]. Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Aliment Pharmacol Ther. 2012 Sep;36(5):437-48. doi: 10.1111/j.1365-2036.2012.05208.x.
[3]. Lucak S.Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.Therap Adv Gastroenterol. 2012 Jul;5(4):215-8.
[4]. Nicandro JP, Shin P, Chuang E.Evaluation of treatment continuation with alosetron by IBS-D severity criteria.Curr Med Res Opin. 2012 Mar;28(3):449-56.